Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective

Area of Science:

• Immunology
• Oncology
• Structural Biology

Background:

• Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are crucial in suppressing T cell activity and enabling cancer immune evasion.
• Overexpression of PD-L1 on cancer cells facilitates immune escape.
• Therapeutic antibodies targeting the PD-1/PD-L1 pathway have emerged as a significant class of cancer treatments.

Purpose of the Study:

• To review the clinical applications and adverse effects of approved anti-PD-1 and anti-PD-L1 antibodies.
• To analyze the structural similarities and differences between the PD-1/PD-L1 interface and antibody epitopes.
• To provide insights for the development of novel PD-1 and PD-L1 blocking agents.

Main Methods:

• Review of clinical applications and adverse effects of approved anti-PD-1 and anti-PD-L1 therapies.
• Analysis of crystal structures of PD-1/PD-L1 complexes and antibody-target interactions.
• Detailed examination of contact residues at the ligand-receptor and antibody-target interfaces.

Main Results:

• Anti-PD-1/PD-L1 therapies demonstrate a wide range of clinical applications, unlike many other therapeutic antibodies.
• These targeted immunotherapies are associated with notable adverse effects.
• Structural analysis reveals partial overlap in contact residues between PD-1/PD-L1 interactions and antibody recognition sites.

Conclusions:

• The broad clinical utility of anti-PD-1/PD-L1 antibodies underscores their importance in cancer immunotherapy.
• Understanding and managing adverse effects are critical for patient safety.
• Characterization of antibody-recognized structural domains can inform the design of next-generation PD-1/PD-L1 inhibitors.